Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Screeners that run automatically... and then email you the results! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Lobe Sciences Ltd (LOBE.CN)
Lobe Sciences Ltd (LOBE.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 4,654
  • Shares Outstanding, K 155,136
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,253 K
  • 60-Month Beta 3.49
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade LOBE.CN with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.15
  • Most Recent Earnings -0.01 on N/A
  • Next Earnings Date N/A
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.025 +20.00%
on 05/09/23
0.040 -25.00%
on 05/17/23
unch (unch)
since 04/26/23
3-Month
0.025 +20.00%
on 05/09/23
0.045 -33.33%
on 03/07/23
-0.005 (-14.29%)
since 02/24/23
52-Week
0.025 +20.00%
on 05/09/23
0.290 -89.66%
on 09/09/22
-0.060 (-66.67%)
since 05/26/22

Most Recent Stories

More News
Lobe Sciences, Ltd. Provides Update on Vitamind

Vancouver, British Columbia--(Newsfile Corp. - April 21, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical Company committed to discovering...

LOBEF : 0.0184 (-8.00%)
LOBE.CN : 0.030 (unch)
Lobe Sciences, Ltd. Announces the Acquisition of Altemia(TM) & Company

Move Affirms Lobe's Position as an Orphan/Rare Disease Drug Development Company and expands portfolio to include 4 Orphan Disease Programs The Company expects to Launch Altemia™, a Medical Food, and...

LOBEF : 0.0184 (-8.00%)
LOBE.CN : 0.030 (unch)
Lobe Sciences to Present at Sequire Cannabis & Psychedelics Conference April 5, 2023

Vancouver, British Columbia--(Newsfile Corp. - April 4, 2023) -  Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company") a North American Biopharmaceutical company committed to discovering...

LOBEF : 0.0184 (-8.00%)
LOBE.CN : 0.030 (unch)
Lobe Sciences Ltd. Announces That The Drug Enforcement Administration Has Issued The Initial 2023 Quota Allowing Export Of L-130

Dosing In Human Clinical Trial To Commence Within WeeksVancouver, British Columbia--(Newsfile Corp. - March 22, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North...

LOBEF : 0.0184 (-8.00%)
LOBE.CN : 0.030 (unch)
Lobe Sciences Ltd. Announces Exclusive Collaboration with Quality Chemical Laboratories LLC

Quality Chemical Laboratories LLC ("QCL") has developed a synthetic pathway for psilocybin, psilocin and psilocin analogues exclusively for Lobe SciencesQCL agrees to supply Lobe Sciences research and...

LOBEF : 0.0184 (-8.00%)
LOBE.CN : 0.030 (unch)
Lobe Sciences, Ltd. Announces USD$250,000 Convertible Note Financing and Warrant Issuance

Vancouver, British Columbia--(Newsfile Corp. - February 10, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering...

LOBEF : 0.0184 (-8.00%)
LOBE.CN : 0.030 (unch)
Lobe Sciences Congratulates Australia for Becoming the First Nation to Approve the Medicinal Use of Psilocybin and MDMA

Vancouver, British Columbia--(Newsfile Corp. - February 6, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American Biopharmaceutical company committed to discovering...

LOBEF : 0.0184 (-8.00%)
LOBE.CN : 0.030 (unch)
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry

EQNX::TICKER_START (OTCQB:LOBEF),(NASDAQ:ATAI),(NASDAQ:CMPS),(NYSE:CYBN),(NASDAQ:MNMD) EQNX::TICKER_END

CYBN.NE : 0.395 (unch)
MMED.NE : 4.830 (+6.62%)
LOBEF : 0.0184 (-8.00%)
LOBE.CN : 0.030 (unch)
ATAI : 1.7700 (unch)
CMPS : 7.65 (+2.27%)
CYBN : 0.2925 (+5.41%)
MNMD : 3.54 (+5.52%)
Psychedelic-Derived Medicines for Neurologic Conditions Fueling Large Revenue Growth in Projected $4 Billion Dollar Industry

/PRNewswire/ -- Even during the recent global supply chain problems, certain markets have continued to show growth. The psychedelic drugs markets is one of...

LOBE.CN : 0.030 (unch)
LOBEF : 0.0184 (-8.00%)
ATAI : 1.7700 (unch)
CMPS : 7.65 (+2.27%)
CYBN : 0.2925 (+5.41%)
MNMD : 3.54 (+5.52%)
Lobe Sciences, Ltd. Enters Collaborative Clinical Research Agreement with Integrative Headache Medicine of New York to Study the Effects of L-130 in the Treatment of Chronic Cluster Headache

Dr. Lauren R. Natbony to be Principal InvestigatorVancouver, British Columbia--(Newsfile Corp. - January 26, 2023) - Lobe Sciences Ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a North American...

LOBEF : 0.0184 (-8.00%)
LOBE.CN : 0.030 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.030
2nd Resistance Point 0.030
1st Resistance Point 0.030
Last Price 0.030
1st Support Level 0.030
2nd Support Level 0.030
3rd Support Level 0.030

See More

52-Week High 0.290
Fibonacci 61.8% 0.189
Fibonacci 50% 0.158
Fibonacci 38.2% 0.126
Last Price 0.030
52-Week Low 0.025

See More

Business Summary

Lobe Sciences Ltd is a technology and services company that provides real estate, financial, management, IP, and branding support for the development of transformational medicine. It is working to develop effective psilocybin-based therapeutics for the treatment of mild traumatic brain injuries and post-traumatic...

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar